Fourth quarter and full year 2019 results

Sanofi delivers strong 2019 business EPS growth of 6.8% at CER

Fourth quarter and full year 2019 results were reviewed by management during a conference call with the financial community. The presentation was followed by a Q&A session.

• Recorded audio webcast
• Presentation
• Clinical trials appendix
• Press release
• Q4 and full year 2019 income statements, cash flow statements, balance sheet
• Q4 and full year 2019 net sales by GBU, franchise, geographic region and product
• Download infographic
• Pre-quarterly results communication